Stock Events

Stock Events

Selecta Biosciences 

0
74
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q1 2026
Next
-1.24
-1.08
-0.91
-0.74
Expected EPS
-0.767328685
Actual EPS
N/A

Financials

-4,565.04%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.46MRevenue
-112.38MNet Income

Analyst Ratings

24.74Average Price Target
The highest estimate is 33.39.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1S7.STU. It's not an investment recommendation.
Apple
6
AAPL
Microsoft
6
MSFT
Amazon
6
AMZN
SoFi Technologies
6
SOFI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, competing in the same space as Cartesian's cell therapy products.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR-T therapies, which puts them in direct competition with Cartesian.
Novartis
NVS
Mkt Cap293.94B
Novartis is a large pharmaceutical company with Kymriah, a CAR-T cell therapy for cancer, making it a competitor in Cartesian's market.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, owning Kite Pharma, competes in the CAR-T and cell therapy space, directly challenging Cartesian's therapeutic approaches.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is involved in various therapeutic areas, including investments in gene therapy and cell therapy, potentially competing with Cartesian's technologies.

About

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Dr. Carsten Brunn Ph.D.
Employees
37
Country
United States
ISIN
US8162121045

Listings

STU
DE
1S70.STU
MU
DE
1S70.MU
STU
DE
1S7.STU
F
DE
1S70.F

0 Comments

Share your thoughts

FAQ

What is Selecta Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Selecta Biosciences stocks are traded under the ticker 1S7.STU.
When is the next Selecta Biosciences earnings date?▼
Selecta Biosciences is going to release the next earnings report on August 06, 2026.
What were Selecta Biosciences earnings last quarter?▼
1S7.STU earnings for the last quarter are -1.24 EUR per share, whereas the estimation was -0.74 EUR resulting in a -67.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Selecta Biosciences revenue for the last year?▼
Selecta Biosciences revenue for the last year amounts to 2.46M EUR.
What is Selecta Biosciences net income for the last year?▼
1S7.STU net income for the last year is -112.38M EUR.
How many employees does Selecta Biosciences have?▼
As of July 19, 2026, the company has 37 employees.
In which sector is Selecta Biosciences located?▼
Selecta Biosciences operates in the Health & Wellness sector.
When did Selecta Biosciences complete a stock split?▼
Selecta Biosciences has not had any recent stock splits.
Where is Selecta Biosciences headquartered?▼
Selecta Biosciences is headquartered in Gaithersburg, United States.